Mayzent 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
PSUSA/10818
Periodic Safety Update EU Single assessment - 
09/11/2023 
05/01/2024 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202303 
siponimod 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10818/202303. 
IAIN/0027 
B.II.b.1.a - Replacement or addition of a 
22/12/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
site 
IB/0026/G 
This was an application for a group of variations. 
13/12/2023 
n/a 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.d.z - Change in control of the Finished Product - 
Other variation 
II/0023 
Update of section 5.1 of the SmPC in order to 
30/11/2023 
SmPC 
Section 5.1 of the SmPC has been updated in order to 
present data on the effect of siponimod on delaying 
the progression to EDSS ≥7 (time-to-wheelchair) 
based on post-hoc analysis of study CBAF312A2304 
(EXPAND). 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IA/0025/G 
This was an application for a group of variations. 
07/09/2023 
n/a 
present data on the effect of siponimod on delaying the 
progression to EDSS ≥7 (time-to-wheelchair) based on 
post-hoc analysis of study CBAF312A2304 (EXPAND). 
For more information, please refer to the Summary of 
Product Characteristics. 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 2/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0024/G 
This was an application for a group of variations. 
25/08/2023 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
II/0020 
Update of sections 4.4 and 4.8 of the SmPC in order 
06/07/2023 
05/01/2024 
SmPC and PL 
Update of sections 4.4 and 4.8 of the SmPC in order to add 
to add “Progressive multifocal leukoencephalopathy 
(PML)” to the list of adverse drug reactions (ADRs) 
with frequency “not know” based on post-marketing 
data. The Annex II (Physician’s Checklist), and 
Package Leaflet are updated accordingly.  
The RMP version 6.0 has also been submitted. In 
addition, the MAH took the opportunity to update the 
text regarding herpes viral infection in the Package 
Leaflet in alignment with the currently approved 
SmPC. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0021 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
05/04/2023 
n/a 
“Progressive multifocal leukoencephalopathy (PML)” to the 
list of adverse drug reactions (ADRs) with frequency “not 
know” based on post-marketing data. The Annex II 
(Physician’s Checklist), and Package Leaflet are updated 
accordingly. The RMP version 6.0 has also been submitted. 
In addition, the MAH took the opportunity to update the 
text regarding herpes viral infection in the Package Leaflet 
in alignment with the currently approved SmPC.  
The requested variation proposed amendments to the 
Summary of Product Characteristics and Package Leaflet 
and to the Risk Management Plan (RMP). 
For more information, please refer to the Summary of 
Product Characteristics. 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/10818
Periodic Safety Update EU Single assessment - 
10/11/2022 
12/01/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202203 
siponimod 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10818/202203. 
PSUSA/10818
Periodic Safety Update EU Single assessment - 
19/05/2022 
18/07/2022 
SmPC, Annex 
Refer to Scientific conclusions and grounds recommending 
/202109 
siponimod 
II and PL 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10818/202109. 
IG/1521 
B.II.b.1.a - Replacement or addition of a 
23/06/2022 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0016/G 
This was an application for a group of variations. 
01/06/2022 
n/a 
B.I.a.3.b - Change in batch size (including batch size 
ranges) of AS or intermediate - Downscaling down to 
10-fold 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IB/0015/G 
This was an application for a group of variations. 
08/03/2022 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
X/0007 
Annex I_2.(c) Change or addition of a new 
16/12/2021 
16/02/2022 
SmPC, 
strength/potency 
Labelling and 
PL 
II/0011/G 
This was an application for a group of variations. 
11/11/2021 
16/02/2022 
SmPC 
For more information, please refer to the Summary of 
Page 5/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product Characteristics. 
Update of section 4.5 of the SmPC to clarify the 
CYP2C9/CYP3A4 inhibitors/inducers information. 
Update of section 5.2 to add information regarding 
CYP2C9 genotypes less frequent alleles. 
Update of sections 4.4 and 4.5 of the SmPC to add 
information in case of administration of non-live 
attenuated vaccines, based on the vaccination study 
A2130. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
PSUSA/10818
Periodic Safety Update EU Single assessment - 
28/10/2021 
n/a 
PRAC Recommendation - maintenance 
/202103 
siponimod 
IAIN/0013/G 
This was an application for a group of variations. 
06/10/2021 
16/02/2022 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
A.5.b - Administrative change - Change in the name 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0012 
B.I.a.3.a - Change in batch size (including batch size 
06/08/2021 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IB/0009/G 
This was an application for a group of variations. 
13/07/2021 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
PSUSA/10818
Periodic Safety Update EU Single assessment - 
09/04/2021 
n/a 
PRAC Recommendation - maintenance 
/202009 
siponimod 
IA/0006/G 
This was an application for a group of variations. 
22/01/2021 
n/a 
B.II.d.1.a - Change in the specification parameters 
Page 7/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
PSUSA/10818
Periodic Safety Update EU Single assessment - 
12/11/2020 
07/01/2021 
SmPC, Annex 
Refer to Scientific conclusions and grounds recommending 
/202003 
siponimod 
II and PL 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10818/202003. 
IAIN/0004 
B.II.b.2.c.2 - Change to importer, batch release 
21/08/2020 
07/01/2021 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Including batch control/testing 
IB/0002/G 
This was an application for a group of variations. 
02/04/2020 
07/01/2021 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
IAIN/0001 
B.II.e.5.a.1 - Change in pack size of the finished 
17/02/2020 
07/01/2021 
SmPC, 
product - Change in the number of units (e.g. 
Labelling and 
tablets, ampoules, etc.) in a pack - Change within 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
PL 
Page 9/9 
 
 
 
 
 
 
 
